Business Wire

Lake House Group Chairman Donates 2.5 Million Masks to European Governments

29.4.2020 07:14:00 EEST | Business Wire | Press release

Share

In response to the impact of COVID-19 on European communities, Lake House Group Chairman Charles Brown has donated and coordinated delivery of 2.5 million masks to three European nations in order to stem the spread of the virus. He said “Masks are a low-cost, effective intervention for stopping the spread of the virus and getting people back to work safely.”

A Hong Kong native with European roots, Brown has donated one million masks each to the Kingdom of Spain and the Federal Republic of Germany, with an additional 500,000 masks designated for Région Sud in France. “The masks landed in Spain and Germany on 15 and 19 April, respectively, and the masks bound for southern France are currently in transit,” reported Torsten Hartmann, Managing Director for Europe in Lake House’s London office.

While traveling in Europe prior to widespread lockdowns, Brown noted with concern that few European citizens wore masks in public. Regarding Hong Kong’s low number of confirmed cases since the outbreak began there on 23 January, Brown stated “The 2003 SARS epidemic taught Hong Kongers to be vigilant about wearing masks, and that experience shows.”

The donation efforts have been spearheaded by Brian Lu, Venture Partner at the Japanese venture capital firm Infinity Ventures, in which Charles Brown is a Limited Partner. The firm’s portfolio company, Hong Kong-based logistics startup Buyandship, has worked to ensure the masks are delivered with as little burden as possible on the governments receiving the donations.

According to Lu, “We’ve seen how tough it’s been for governments to obtain masks from trusted sources and get them delivered efficiently, so we’re proud to be able to help these countries get masks into people’s hands as quickly as possible.”

“Giving money is an easy thing if you have it, but a more effective thing is to deliver the goods to the point where they are needed, and that’s what we’re trying to achieve here,” added Lake House’s Charles Brown. “I hope our efforts are able to spark other private donors to use their resources and connections to make similar efforts,” he said.

About Lake House Group

Established in 1995, Lake House Group is a private investment company founded by Hong Kong native Charles Brown, who is also Chairman Emeritus and Founding Board Member of the United Nations Peace Development Foundation in China. Lake House is led by CEO David Timblick, and invests in businesses across the globe at every stage. With offices in Hong Kong and London, the firm is involved in projects and investments in excess of US$15 billion across 15 countries.

About Infinity Ventures

Infinity Ventures is a venture capital firm, focused on early stage Internet companies, founded in Japan in 2008, with offices in Tokyo, Taipei, and Beijing. The firm manages $255M USD, and has invested in 91 startups and produced 9 IPOs. Since its founding, Infinity Ventures has grown alongside its portfolio companies to build category-leading innovators and unicorns including Groupon, Farfetch, freee, Yeahka, WealthNavi, and 17 Media.

About Buyandship

Buyandship is a cross-border e-commerce logistics company established in 2014. The company provides a one-stop transit service for goods bought in the United States, United Kingdom, Japan, Korea, and China. Buyandship currently maintains warehouses in multiple countries, with daily scheduled flights to Hong Kong and other markets in Asia.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Harrington, Infinity Ventures
holly@infinityventures.com
+886936845447

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye